Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...
The second person ever has received a transplant with a genetically modified pig kidney.
Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.
CRISPR (NASDAQ:CRSP) develops gene-based medicines using its CRISPR/Cas9 platform, with therapies targeting diseases like ...
Genesis announced that it has completed its second successful human transplant with a genetically engineered pig kidney, with ...
A team at Massachusetts General Hospital led by Harvard Medical School physician-scientists has for the second time ...
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ ...
This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...
Liposuction and plastic surgery aren't often mentioned in the same breath as cancer. But they are the inspiration for a new approach to treating cancer that uses engineered fat cells to deprive tumors ...
Scientists at UC San Francisco have pioneered a groundbreaking approach to fighting cancer using engineered fat cells. By ...